Rx Price Watch Report: Brand Name Drug Prices Increase More than Twice as Fast as Inflation in 2018

2019 ◽  
Author(s):  
Stephen W. Schondelmeyer ◽  
Leigh Purvis
Keyword(s):  
2021 ◽  
Vol 4 (5) ◽  
pp. e218816
Author(s):  
Benjamin N. Rome ◽  
William B. Feldman ◽  
Rishi J. Desai ◽  
Aaron S. Kesselheim

2018 ◽  
Vol 168 (6) ◽  
pp. 436 ◽  
Author(s):  
Ge Bai ◽  
Aditi P. Sen ◽  
Gerard F. Anderson

2021 ◽  
pp. 38-61
Author(s):  
Neumann Peter J. ◽  
Cohen Joshua T. ◽  
Ollendorf Daniel A

This chapter explores proposed solutions for high drug prices. They include measures to rein in “middlemen” pharmacy benefit managers who may artificially inflate prices; increase generic drug competition to prevent price spikes for older, off-patent drugs; enhance competition for new drugs after brand-name products reach the intended period of market protection; align US drug prices with the lower prices available in other wealthy countries; and leverage the collective bargaining power of government payers to compel drug companies to accept lower prices for their products. Policies that force drug prices down can save money but risk choking off the development of important new advances, limiting patient access to their health benefits. Moreover, the policy solutions typically offered are incremental solutions that will likely put a modest dent in the nation’s $500 billion annual drug bill. Most important, they fail to link a drug’s price to its value.


Sign in / Sign up

Export Citation Format

Share Document